Overview

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This was a 52-week, multicenter, non-randomized, open-label, Phase 3 long-term safety study in participants with type 2 diabetes mellitus who have inadequate glycemic control with monotherapy of oral antihyperglycemic medication (OAM).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
2,4-thiazolidinedione
Biguanides
Dulaglutide
Glycoside Hydrolase Inhibitors
Hypoglycemic Agents